A5058875978- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Valve Diseases and Treatments
- Atrial Fibrillation Management and Outcomes
- Cardiac, Anesthesia and Surgical Outcomes
- Peripheral Artery Disease Management
- Venous Thromboembolism Diagnosis and Management
- Mechanical Circulatory Support Devices
- Infective Endocarditis Diagnosis and Management
- Cerebrovascular and Carotid Artery Diseases
- Cardiac Structural Anomalies and Repair
- Cardiac Arrest and Resuscitation
- Blood Pressure and Hypertension Studies
- Vascular Procedures and Complications
- Health Systems, Economic Evaluations, Quality of Life
- Cardiovascular Function and Risk Factors
- COVID-19 Clinical Research Studies
- Aortic aneurysm repair treatments
- Renal and Vascular Pathologies
- Hemodynamic Monitoring and Therapy
- Cardiac and Coronary Surgery Techniques
- Aortic Disease and Treatment Approaches
- Heart Rate Variability and Autonomic Control
Cardiovascular Research Foundation
2016-2025
Columbia University
2016-2025
New York Hospital Queens
2016-2025
NewYork–Presbyterian Hospital
2016-2025
Columbia University Irving Medical Center
2016-2025
Beth Israel Deaconess Medical Center
2006-2024
Harvard University
2004-2024
Texas Health Dallas
2015-2024
Presbyterian Hospital
2013-2024
Duke University
2015-2024
Treatment with the direct thrombin inhibitor bivalirudin, as compared heparin plus glycoprotein IIb/IIIa inhibitors, results in similar suppression of ischemia while reducing hemorrhagic complications patients stable angina and non-ST-segment elevation acute coronary syndromes who are undergoing percutaneous intervention (PCI). The safety efficacy bivalirudin high-risk unknown.We randomly assigned 3602 ST-segment myocardial infarction presented within 12 hours after onset symptoms were...
The safety of drug-eluting stents has been called into question by recent reports increased stent thrombosis, myocardial infarction, and death. Such studies have inconclusive because their insufficient size, the use historical controls, a limited duration follow-up, lack access to original source data.We performed pooled analysis data from four double-blind trials in which 1748 patients were randomly assigned receive either sirolimus-eluting or bare-metal five 3513 paclitaxel-eluting stents;...
ObjectivesThe aim of the current Valve Academic Research Consortium (VARC)-2 initiative was to revisit selection and definitions transcatheter aortic valve implantation (TAVI)clinical endpoints make them more suitable present future needs clinical trials. In addition, this document is intended expand understanding patient risk stratification case selection.
ObjectivesThe aim of the current Valve Academic Research Consortium (VARC)-2 initiative was to revisit selection and definitions transcatheter aortic valve implantation (TAVI) clinical endpoints make them more suitable present future needs trials. In addition, this document is intended expand understanding patient risk stratification case selection.BackgroundA recent study confirmed that VARC have already been incorporated into research practice represent a new standard for consistency in...
Thrombotic events are commonly reported in critically ill patients with COVID-19. Limited data exist to guide the intensity of antithrombotic prophylaxis.To evaluate effects intermediate-dose vs standard-dose prophylactic anticoagulation among COVID-19 admitted intensive care unit (ICU).Multicenter randomized trial a 2 × factorial design performed 10 academic centers Iran comparing (first hypothesis) and statin therapy matching placebo (second hypothesis; not this article) adult ICU Patients...
Information about a real patient is presented in stages (boldface type) to expert clinicians (Drs Uriel and Sayer), who respond the information share their reasoning with reader (regular type
It has been suggested that the survival benefit associated with primary percutaneous coronary intervention (PPCI) in ST-segment elevation myocardial infarction may be attenuated if door-to-balloon (DB) time is delayed by >1 hour beyond door-to-needle (DN) times for fibrinolytic therapy. Whereas DB are rapid randomized trials, they often prolonged routine practice. We hypothesized clinical practice, longer DB-DN would higher mortality rates and reduced PPCI advantage. also addition to delays,...